Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100


The development and validation of a human screening model of tobacco abstinence.

Grabski M, Curran HV, Nutt DJ, Husbands SM, Ferguson SG, Munafò MR.

Drug Alcohol Depend. 2020 Jan 1;206:107720. doi: 10.1016/j.drugalcdep.2019.107720. Epub 2019 Nov 6.


OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention.

Maguire DR, Gerak LR, Cami-Kobeci G, Husbands SM, France CP, Belli B, Flynn P.

J Pharmacol Exp Ther. 2020 Feb;372(2):205-215. doi: 10.1124/jpet.119.261511. Epub 2019 Nov 20.


Synthetic Cannabinoid Receptor Agonists Detection Using Fluorescence Spectral Fingerprinting.

May B, Naqi HA, Tipping M, Scott J, Husbands SM, Blagbrough IS, Pudney CR.

Anal Chem. 2019 Oct 15;91(20):12971-12979. doi: 10.1021/acs.analchem.9b03037. Epub 2019 Oct 3.


Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of µ-Opioid Receptor Agonists but Not Prolonged Precipitated Withdrawal in Rats.

Gerak LR, Minervini V, Latham E, Ghodrati S, Lillis KV, Wooden J, Disney A, Husbands SM, France CP.

J Pharmacol Exp Ther. 2019 Nov;371(2):507-516. doi: 10.1124/jpet.119.260331. Epub 2019 Aug 22.


Simultaneous Transdermal Delivery of Buprenorphine Hydrochloride and Naltrexone Hydrochloride by Iontophoresis.

Cordery SF, Husbands SM, Bailey CP, Guy RH, Delgado-Charro MB.

Mol Pharm. 2019 Jun 3;16(6):2808-2816. doi: 10.1021/acs.molpharmaceut.9b00337. Epub 2019 May 22.


Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys.

Flynn SM, Epperly PM, Davenport AT, Cami-Kobeci G, Husbands SM, Ko MC, Czoty PW.

Neuropsychopharmacology. 2019 Jul;44(8):1476-1484. doi: 10.1038/s41386-019-0390-z. Epub 2019 Apr 10.


BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates.

Kiguchi N, Ding H, Cami-Kobeci G, Sukhtankar DD, Czoty PW, DeLoid HB, Hsu FC, Toll L, Husbands SM, Ko MC.

Br J Anaesth. 2019 Jun;122(6):e146-e156. doi: 10.1016/j.bja.2018.10.065. Epub 2019 Mar 1.


Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel μ-Opioid Receptor Antagonist Methocinnamox in Rhesus Monkeys.

Gerak LR, Maguire DR, Woods JH, Husbands SM, Disney A, France CP.

J Pharmacol Exp Ther. 2019 Feb;368(2):229-236. doi: 10.1124/jpet.118.253286. Epub 2018 Nov 21.


Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys.

Maguire DR, Gerak LR, Woods JH, Husbands SM, Disney A, France CP.

J Pharmacol Exp Ther. 2019 Jan;368(1):88-99. doi: 10.1124/jpet.118.252353. Epub 2018 Nov 6.


Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile.

Kumar V, Polgar WE, Cami-Kobeci G, Thomas MP, Khroyan TV, Toll L, Husbands SM.

Front Psychiatry. 2018 Sep 19;9:430. doi: 10.3389/fpsyt.2018.00430. eCollection 2018.


Additive Effects of 3,4-Methylenedioxymethamphetamine (MDMA) and Compassionate Imagery on Self-Compassion in Recreational Users of Ecstasy.

Kamboj SK, Walldén YSE, Falconer CJ, Alotaibi MR, Blagbrough IS, Husbands SM, Freeman TP.

Mindfulness (N Y). 2018;9(4):1134-1145. doi: 10.1007/s12671-017-0849-0. Epub 2017 Nov 4.


Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 Binding Site in Human Brain.

Tyacke RJ, Myers JFM, Venkataraman A, Mick I, Turton S, Passchier J, Husbands SM, Rabiner EA, Gunn RN, Murphy PS, Parker CA, Nutt DJ.

J Nucl Med. 2018 Oct;59(10):1597-1602. doi: 10.2967/jnumed.118.208009. Epub 2018 Mar 9.


Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed κ/μ receptor antagonist properties, in mice.

Almatroudi A, Ostovar M, Bailey CP, Husbands SM, Bailey SJ.

Br J Pharmacol. 2018 Jul;175(14):2869-2880. doi: 10.1111/bph.14060. Epub 2017 Nov 6.


A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.

Ding H, Czoty PW, Kiguchi N, Cami-Kobeci G, Sukhtankar DD, Nader MA, Husbands SM, Ko MC.

Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):E5511-8. doi: 10.1073/pnas.1605295113. Epub 2016 Aug 29.


Behavioural tasks sensitive to acute abstinence and predictive of smoking cessation success: a systematic review and meta-analysis.

Grabski M, Curran HV, Nutt DJ, Husbands SM, Freeman TP, Fluharty M, Munafò MR.

Addiction. 2016 Dec;111(12):2134-2144. doi: 10.1111/add.13507. Epub 2016 Aug 8. Review.


Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice.

Zielińska M, Ben Haddou T, Cami-Kobeci G, Sałaga M, Jarmuż A, Padysz M, Kordek R, Spetea M, Husbands SM, Fichna J.

Eur J Pharmacol. 2015 Oct 15;765:582-90. doi: 10.1016/j.ejphar.2015.09.021. Epub 2015 Sep 25.


Structural insights into µ-opioid receptor activation.

Huang W, Manglik A, Venkatakrishnan AJ, Laeremans T, Feinberg EN, Sanborn AL, Kato HE, Livingston KE, Thorsen TS, Kling RC, Granier S, Gmeiner P, Husbands SM, Traynor JR, Weis WI, Steyaert J, Dror RO, Kobilka BK.

Nature. 2015 Aug 20;524(7565):315-21. doi: 10.1038/nature14886. Epub 2015 Aug 5.


Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice.

Almatroudi A, Husbands SM, Bailey CP, Bailey SJ.

J Psychopharmacol. 2015 Jul;29(7):812-21. doi: 10.1177/0269881115586937. Epub 2015 Jun 4.


Role of G Protein-Coupled Receptor Kinases 2 and 3 in μ-Opioid Receptor Desensitization and Internalization.

Lowe JD, Sanderson HS, Cooke AE, Ostovar M, Tsisanova E, Withey SL, Chavkin C, Husbands SM, Kelly E, Henderson G, Bailey CP.

Mol Pharmacol. 2015 Aug;88(2):347-56. doi: 10.1124/mol.115.098293. Epub 2015 May 26.


C7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors.

Cueva JP, Roche C, Ostovar M, Kumar V, Clark MJ, Hillhouse TM, Lewis JW, Traynor JR, Husbands SM.

J Med Chem. 2015 May 28;58(10):4242-9. doi: 10.1021/acs.jmedchem.5b00130. Epub 2015 May 6.


Selectivity and anti-Parkinson's potential of thiadiazolidinone RGS4 inhibitors.

Blazer LL, Storaska AJ, Jutkiewicz EM, Turner EM, Calcagno M, Wade SM, Wang Q, Huang XP, Traynor JR, Husbands SM, Morari M, Neubig RR.

ACS Chem Neurosci. 2015 Jun 17;6(6):911-9. doi: 10.1021/acschemneuro.5b00063. Epub 2015 Apr 20.


¹H, ¹³C, ¹⁵N HMBC, and ¹⁹F NMR spectroscopic characterisation of seized flephedrone, cut with benzocaine.

Alotaibi MR, Husbands SM, Blagbrough IS.

J Pharm Biomed Anal. 2015 Mar 25;107:535-8. doi: 10.1016/j.jpba.2014.12.033. Epub 2014 Dec 30.


Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.

Bailey CP, Husbands SM.

Expert Opin Drug Discov. 2014 Nov;9(11):1333-44. doi: 10.1517/17460441.2014.964203. Epub 2014 Sep 25. Review.


Pyrrolo- and pyridomorphinans: non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists.

Kumar V, Clark MJ, Traynor JR, Lewis JW, Husbands SM.

Bioorg Med Chem. 2014 Aug 1;22(15):4067-72. doi: 10.1016/j.bmc.2014.05.065. Epub 2014 Jun 12.


BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.

Khroyan TV, Wu J, Polgar WE, Cami-Kobeci G, Fotaki N, Husbands SM, Toll L.

Br J Pharmacol. 2015 Jan;172(2):668-80. doi: 10.1111/bph.12796. Epub 2014 Nov 5.


Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.

Sobczak M, Cami-Kobeci G, Sałaga M, Husbands SM, Fichna J.

Eur J Pharmacol. 2014 Aug 5;736:63-9. doi: 10.1016/j.ejphar.2014.04.038. Epub 2014 May 6.


Selectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity.

Kumar V, Ridzwan IE, Grivas K, Lewis JW, Clark MJ, Meurice C, Jimenez-Gomez C, Pogozheva I, Mosberg H, Traynor JR, Husbands SM.

J Med Chem. 2014 May 22;57(10):4049-57. doi: 10.1021/jm401964y. Epub 2014 May 9.


Evaluation of 11C-BU99008, a PET ligand for the imidazoline2 binding sites in rhesus brain.

Parker CA, Nabulsi N, Holden D, Lin SF, Cass T, Labaree D, Kealey S, Gee AD, Husbands SM, Quelch D, Carson RE, Nutt DJ, Huang Y, Tyacke RJ.

J Nucl Med. 2014 May;55(5):838-44. doi: 10.2967/jnumed.113.131854. Epub 2014 Apr 7.


Characterization of BU09059: a novel potent selective κ-receptor antagonist.

Casal-Dominguez JJ, Furkert D, Ostovar M, Teintang L, Clark MJ, Traynor JR, Husbands SM, Bailey SJ.

ACS Chem Neurosci. 2014 Mar 19;5(3):177-84. doi: 10.1021/cn4001507. Epub 2014 Jan 28.


Palladium-mediated oxidative carbonylation reactions for the synthesis of (11) C-radiolabelled ureas.

Kealey S, Husbands SM, Bennacef I, Gee AD, Passchier J.

J Labelled Comp Radiopharm. 2014 Apr;57(4):202-8. doi: 10.1002/jlcr.3151. Epub 2013 Dec 11.


Loop diuretics are open-channel blockers of the cystic fibrosis transmembrane conductance regulator with distinct kinetics.

Ju M, Scott-Ward TS, Liu J, Khuituan P, Li H, Cai Z, Husbands SM, Sheppard DN.

Br J Pharmacol. 2014 Jan;171(1):265-78. doi: 10.1111/bph.12458.


Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.

Sukhtankar DD, Zaveri NT, Husbands SM, Ko MC.

J Pharmacol Exp Ther. 2013 Jul;346(1):11-22. doi: 10.1124/jpet.113.203984. Epub 2013 May 7.


Orvinols with mixed kappa/mu opioid receptor agonist activity.

Greedy BM, Bradbury F, Thomas MP, Grivas K, Cami-Kobeci G, Archambeau A, Bosse K, Clark MJ, Aceto M, Lewis JW, Traynor JR, Husbands SM.

J Med Chem. 2013 Apr 25;56(8):3207-16. doi: 10.1021/jm301543e. Epub 2013 Apr 3.


A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm.

Cordery SF, Taverner A, Ridzwan IE, Guy RH, Delgado-Charro MB, Husbands SM, Bailey CP.

Addict Biol. 2014 Jul;19(4):575-86. doi: 10.1111/adb.12020. Epub 2012 Dec 14.


Imaging imidazoline-I2 binding sites in porcine brain using 11C-BU99008.

Kealey S, Turner EM, Husbands SM, Salinas CA, Jakobsen S, Tyacke RJ, Nutt DJ, Parker CA, Gee AD.

J Nucl Med. 2013 Jan;54(1):139-44. doi: 10.2967/jnumed.112.108258. Epub 2012 Dec 5.


In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor.

Casal-Dominguez JJ, Clark M, Traynor JR, Husbands SM, Bailey SJ.

J Psychopharmacol. 2013 Feb;27(2):192-202. doi: 10.1177/0269881112464828. Epub 2012 Oct 31.


Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects.

Moynihan HA, Derrick I, Broadbear JH, Greedy BM, Aceto MD, Harris LS, Purington LC, Thomas MP, Woods JH, Traynor JR, Husbands SM, Lewis JW.

J Med Chem. 2012 Nov 26;55(22):9868-74. doi: 10.1021/jm301096s. Epub 2012 Oct 31.


Small Molecule Inhibitors of Regulator of G Protein Signalling (RGS) Proteins.

Turner EM, Blazer LL, Neubig RR, Husbands SM.

ACS Med Chem Lett. 2012 Feb 9;3(2):146-150.


Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-dihydro-1H-imidazol-2-yl)-1- methyl-1H-indole), for the imidazoline₂ binding site.

Tyacke RJ, Fisher A, Robinson ES, Grundt P, Turner EM, Husbands SM, Hudson AL, Parker CA, Nutt DJ.

Synapse. 2012 Jun;66(6):542-51. doi: 10.1002/syn.21541. Epub 2012 Feb 22.


Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.

Cami-Kobeci G, Polgar WE, Khroyan TV, Toll L, Husbands SM.

J Med Chem. 2011 Oct 13;54(19):6531-7. doi: 10.1021/jm2003238. Epub 2011 Sep 7.


14-Amino-4,5-epoxymorphinan derivatives and their pharmacological actions.

Lewis JW, Husbands SM.

Top Curr Chem. 2011;299:93-119. Review.


Microfluidic reactions using [11C]carbon monoxide solutions for the synthesis of a positron emission tomography radiotracer.

Kealey S, Plisson C, Collier TL, Long NJ, Husbands SM, Martarello L, Gee AD.

Org Biomol Chem. 2011 May 7;9(9):3313-9. doi: 10.1039/c0ob00631a. Epub 2011 Mar 25.


A nanomolar-potency small molecule inhibitor of regulator of G-protein signaling proteins.

Blazer LL, Zhang H, Casey EM, Husbands SM, Neubig RR.

Biochemistry. 2011 Apr 19;50(15):3181-92. doi: 10.1021/bi1019622. Epub 2011 Mar 29.


Synthesis and in vivo brain distribution of carbon-11-labeled δ-opioid receptor agonists.

Pichika R, Jewett DM, Sherman PS, Traynor JR, Husbands SM, Woods JH, Kilbourn MR.

Nucl Med Biol. 2010 Nov;37(8):989-96. doi: 10.1016/j.nucmedbio.2010.06.002. Epub 2010 Jul 24.


Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins.

Blazer LL, Roman DL, Chung A, Larsen MJ, Greedy BM, Husbands SM, Neubig RR.

Mol Pharmacol. 2010 Sep;78(3):524-33. doi: 10.1124/mol.110.065128. Epub 2010 Jun 22.


14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.

Nieland NP, Rennison D, Broadbear JH, Purington L, Woods JH, Traynor JR, Lewis JW, Husbands SM.

J Med Chem. 2009 Nov 12;52(21):6926-30. doi: 10.1021/jm901074a.


Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site.

Kimura A, Tyacke RJ, Robinson JJ, Husbands SM, Minchin MC, Nutt DJ, Hudson AL.

Brain Res. 2009 Jul 7;1279:21-8. doi: 10.1016/j.brainres.2009.04.044. Epub 2009 May 3.


14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.

Moynihan H, Jales AR, Greedy BM, Rennison D, Broadbear JH, Purington L, Traynor JR, Woods JH, Lewis JW, Husbands SM.

J Med Chem. 2009 Mar 26;52(6):1553-7. doi: 10.1021/jm8012272.


Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines.

Cami-Kobeci G, Neal AP, Bradbury FA, Purington LC, Aceto MD, Harris LS, Lewis JW, Traynor JR, Husbands SM.

J Med Chem. 2009 Mar 26;52(6):1546-52. doi: 10.1021/jm8015552.

Supplemental Content

Loading ...
Support Center